{"id":232223,"date":"2010-01-26T14:31:30","date_gmt":"2010-01-26T19:31:30","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=60228"},"modified":"2010-01-26T14:31:30","modified_gmt":"2010-01-26T19:31:30","slug":"prometheus-positions-for-ipo-licenses-novartis-drug","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/232223","title":{"rendered":"Prometheus Positions for IPO, Licenses Novartis Drug"},"content":{"rendered":"\n
Life Sciences<\/a>, deals<\/a>, IPO<\/a><\/div>\n

\t\tBruce V. Bigelow wrote:<\/strong><\/p>\n

Prometheus Laboratories, a San Diego-based specialty pharmaceutical and diagnostics company, says<\/a> it has executed a commercialization deal with Novartis that gives Prometheus exclusive rights to sell aldesleukin (Proleukin) in the United States. Aldesleukin is a recombinant human interleukin-2 for treating metastatic melanoma and metastatic kidney cancer, and generated about $75 million in U.S. sales last year. PE Hub reports<\/a> that Prometheus is in registration for a $100 million IPO, and has raised $73 million in venture funding from DLJ Merchant Banking Partners, Split Rock Partners, New Leaf Ventures, Apax Partners, Wachovia Capital Partners, and Brentwood Venture Capital. Earlier this month, Prometheus secured<\/a> a $210 million loan and a $50 million revolving line of credit.<\/p>\n


<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, deals, IPO Bruce V. Bigelow wrote: Prometheus Laboratories, a San Diego-based specialty pharmaceutical and diagnostics company, says it has executed a commercialization deal with Novartis that gives Prometheus exclusive rights to sell aldesleukin (Proleukin) in the United States. Aldesleukin is a recombinant human interleukin-2 for treating metastatic melanoma and metastatic kidney cancer, and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-232223","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/232223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=232223"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/232223\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=232223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=232223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=232223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}